Search PubMed⌕ Search

Biomedical subjects

U Okamoto

Publications and source records attributed to U Okamoto.

At least 37 records · Page 2Linked to original sources
PubMed1987

New modified activated partial thromboplastin time and prothrombin time methods using a synthetic chromogenic substrate in combination with diazotization.

A chromogenic substrate, H-D-Phe-Pip-Arg-pNA (S-2238) is a highly specific substrate to thrombin and releases p-nitroaniline (pNA) by the action of thrombin. We describe new modified APTT and PT methods using S-2238 in combination with the diazotization of pNA. In the modified APTT method, 100 microliter citrated plasma (diluted to 10-fold), 90 microliter 1 mM S-2238, 100 microliter 20 mM CaCl2 and 100 microliter Actin were mixed in an ice-bath, then incubated for 8 min at 37 degrees C. The reaction was stopped, and the generated pNA was diazotized by adding the following solutions sequentially: 975 microliter 0.04% sodium nitrite, 975 microliter 0.3% ammonium sulfamate and 975 microliter 0.07% N-(l-naphthyl)-ethylenediamine dihydrochloride. Diazotization changed pNA from yellow to pink. Then, absorbance at 545 nm was read, and values were expressed as thrombin units/ml plasma. In the modified PT method, 100 microliter citrated plasma (diluted to 20-fold), 90 microliter 1 mM S-2238 and 200 microliter tissue thromboplastin-C solution were mixed and processed as above. Correlations of the present modified APTT and APTT methods, and of modified PT and PT methods were significant (r = 0.426, p less than 0.01 and r = 0.561, p less than 0.01, respectively).

Aniline Compounds↗
PubMed1987

Increase of nonplasmin fibrinolytic activity in the lung and spleen of streptozotocin-induced diabetic rats.

In streptozotocin-induced diabetes in rats, nonplasmin fibrinolytic activity was found to be significantly increased in the lung and spleen, but not in the liver and kidney. The plasminogen-activator activities, either soluble or insoluble, were almost simultaneously increased in the lung, suggesting the possible release of plasminogen-activator from the lung to the blood. It seems likely that plasminogen-activator of the usual type and nonplasmin protease are also involved in thrombotic disorders in the experimental diabetes.

Animals↗
PubMed1985

Variation in activities of non-plasmin fibrinolytic proteinase and plasminogen-activator in the lung and spleen induced by bacterial endotoxin in rats with special reference to the effects of MD-805.

The behavior of direct fibrinolytic (non-plasmin) proteinase activity and plasminogen-activator activity in the lung and spleen was investigated in rats after a single intravenous injection of bacterial endotoxin, and the influence of thrombin inhibitors on the effects of the endotoxin was assessed. The non-plasmin fibrinolytic activity was markedly increased following a decrease of plasminogen-activator in the lung. In addition, variations in hematological parameters, i.e. a decrease of platelet count, fibrinogen level and antithrombin III, and an increase of blood urea nitrogen and euglobulin fibrinolytic activity, were induced by the injection, indicating the occurrence of disseminated intravascular coagulation. In comparative studies on the effects of the endotoxin injection and thrombin infusion, in the lung and spleen an increase of fibrinolytic proteinase activity was induced in a similar manner; the plasminogen-activator activity in the lung was decreased by the endotoxin injection but not decreased by the thrombin infusion. In prevention studies with heparin and MD-805, the latter was found to prevent the decrease of either fibrinogen or platelet count. However, the former failed to prevent the decrease of platelet count although that of the fibrinogen level was prevented. Heparin and MD-805 exerted no preventive effect on the endotoxin-induced variations of proteinase activity and plasminogen-activator activity in the lung.

Animals↗
PubMed1985

Production of the modified form of human plasminogen by alpha 2-macroglobulin-plasmin complexes.

It has been speculated that the modified form of plasminogen, a precursor of proteolytic enzyme plasmin in plasma, plays an important role in fibrinolysis in the blood. The present study was undertaken to examine the production by alpha 2-macroglobulin-plasmin complexes. alpha 2-Macroglobulin-plasmin complexes were purified from urokinase-activated plasma by affinity chromatography on lysine-Sepharose and gel filtration on Ultrogel AcA 22. The plasmin complex converted native plasminogen into the modified form more easily in the presence of epsilon-aminocaproic acid. The modification of native plasminogen by alpha 2-macroglobulin-bound plasmin was completely inhibited by aprotinin, and partly by soybean trypsin inhibitor. alpha 2-macroglobulin-bound plasmin produced modified plasminogen in human plasma where potent plasmin inhibitors exist, though the degree of production was small. The present results support the speculation of the important role of the modified form in vivo.

Animals↗
PubMed1984

Human leukocyte elastase-like proteinase purified by affinity chromatography with Suc-L-Tyr-D-Leu-D-Val-pNA, and its identification with human spleen fibrinolytic proteinase.

Elastase-like proteinase ( ELP ) extracted with 2 M NaClO4 from human leukocytes was purified by a new affinity chromatography technique with Suc-L-Tyr-D-Leu-D-Val-pNA, following delipidation, salting out and Sephadex gel chromatography. The purified preparation contained practically no chymotrypsin-like proteinase activity, and it was homogeneous on SDS polyacrylamide gel electrophoresis. The enzyme so purified readily degraded fibrin, fibrinogen, elastin and -Val type synthetic peptide substrates, such as Suc-L-Ala-L-Tyr-L-Leu-L-Val-pNA and Suc-L-Tyr-L-Leu-L-Val-pNA. A special increase in ELP activity by adding chaotropic ions was observed. The enzymatic properties of the ELP were very similar to those of spleen fibrinolytic proteinase (SFP). ELP and SFP were identified immunologically using mice antisera against purified ELP .

Adult↗
PubMed1983

Production of the modified form of human plasminogen in the plasma activated by urokinase.

Plasminogen, a precursor of proteolytic enzyme plasmin which lyses thrombi in vivo, is postulated to be adsorbed onto fibrin and is converted into a modified form by plasmin. The properties of the modified form examined in vitro support this hypothesis. Nevertheless, it has been postulated that no conversion of native plasminogen into the modified form occurs in plasma, since alpha 2-plasmin inhibitor rapidly inactivates plasmin formed. However, we suggested production of the modified form in the "post-exercise" plasma. The present study was undertaken to examine production of the modified form in a simpler system, urokinase-activated plasma. The amount of the modified form in the plasma was estimated using the previous method with modification, epsilon-aminocaproic acid-containing polyacrylamide gel disc electrophoresis. The amount in the post-exercise plasma was also re-estimated by the present method. The amount of the modified form increased with the increase in urokinase concentration added to plasma. The presence of the modified form in the post-exercise plasma was also confirmed. The modified form could be produced in the plasma where an excess amount of alpha 2-plasmin inhibitor was expected to exist. The present results indicate that conversion of native plasminogen into the modified form may occur in vivo, supporting the hypothesis mentioned above.

Adult↗
PubMed1982

A partially degraded form of human plasminogen in circulating blood.

A method for separate measurement of the amounts of the native form and partially degraded form of plasminogen and plasmin in human circulating blood was devised based on their different mobilities on disc polyacrylamide gel electrophoresis. The relative amounts in the circulating blood as estimated by the method were as follows: 78.5% native form, 6.1% partially degraded form and 15.5% plasmin, in the resting state of healthy adults. The partially degraded form increased to about 50% after strenuous exercise load. The present study showed that relatively large amounts of the partially degraded form can be produced in the circulating blood, even though abundant plasmin inhibitors exist there. These data suggest that the partially degraded form may play an important role in thrombolysis in vivo.

Electrophoresis, Polyacrylamide Gel↗
PubMed1982

[Fluctuations in pulmonary fibrin decomposing activities (plasmin and non-plasmin activities) in an endotoxin DIC model in rats].

Non-plasmin fibrinolysis enzyme was extracted from the lung and spleen of conventional rats (Thrombos. Haemostas., 1979), although the enzyme was not found in germfree rats, suggesting the possibility that the enzyme may participate in the defence mechanism of the body. The present study was made in an attempt to determine the behavior of non-plasmin fibrinolysis enzyme of the lung tissue in the DIC model of conventional rats induced by a single injection of bacterial endotoxin. The plasminogen-activator activity of the lung tissue, and the fibrinogen level, platelet count, urea nitrogen and plasminogen-activator activity in the blood were also measured. Examination of the lung tissue in the DIC rats indicated a remarkable increase in non-plasmin fibrinolysis activity and a disappearance of plasminogen-activator activity. Inhibitor studies using t-AMCHA and DFP demonstrated that the increased non-plasmin fibrinolysis activity was not derived from activated plasmin, but from serine protease. The disappearance of plasminogen-activator activity in the lung and increase of plasminogen-activator activity in the blood suggested a release of the activator from the lung into the blood due to the endotoxin injection.

Animals↗